Azitra, Inc. Files S-1 Registration Statement

TL;DR

<b>Azitra, Inc. has filed an S-1 registration statement, signaling its intent to go public.</b>

AI Summary

Azitra, Inc. (AZTR) filed a IPO Registration (S-1) with the SEC on January 19, 2024. Azitra, Inc. has filed an S-1 registration statement with the SEC. The filing indicates Azitra, Inc. is incorporated in Delaware. The company's principal executive offices are located at 21 Business Park Drive, Branford, CT 06405. Azitra, Inc. is classified under Standard Industrial Classification code 2834 (Pharmaceutical Preparations). The filing was made on January 19, 2024.

Why It Matters

For investors and stakeholders tracking Azitra, Inc., this filing contains several important signals. This S-1 filing is a prerequisite for Azitra, Inc. to conduct an Initial Public Offering (IPO), allowing it to raise capital from public investors. The detailed information within the S-1 provides potential investors with crucial insights into the company's business, financial condition, and risks before investing.

Risk Assessment

Risk Level: low — Azitra, Inc. shows low risk based on this filing. The filing is a standard S-1 registration statement, indicating preliminary steps towards an IPO rather than immediate financial performance or operational changes.

Analyst Insight

Monitor future filings for details on the IPO, including share price, number of shares offered, and use of proceeds.

Key Numbers

• 2834 — SIC Code (Pharmaceutical Preparations)
• DE — State of Incorporation (Delaware)
• 06405 — ZIP Code (Branford, CT)
• 203-646-6446 — Phone Number (Principal Executive Offices)

Key Players & Entities

• Azitra, Inc. (company) — Registrant
• 2024-01-19 (date) — Filing Date
• S-1 (form) — Filing Type
• Delaware (jurisdiction) — State of Incorporation
• 2834 (industry_code) — Standard Industrial Classification Code
• 21 Business Park Drive, Branford, CT 06405 (address) — Principal Executive Offices
• Francisco D. Salva (person) — Agent for Service
• Greenberg Traurig, LLP (company) — Legal Counsel

Forward-Looking Statements

• Azitra, Inc. will successfully complete a public offering of securities. (Azitra, Inc.) — medium confidence, target: 2024-12-31
• The capital raised from this offering will primarily be used to fund research and development in pharmaceutical preparations. (Azitra, Inc.) — high confidence, target: 2025-01-19

FAQ

Industry Context

Azitra, Inc. operates within the pharmaceutical preparations industry, indicated by its SIC code 2834.

Regulatory Implications

The S-1 filing is a regulatory requirement under the Securities Act of 1933 for companies intending to offer securities to the public.

What Investors Should Do

1. Review the full S-1 filing for detailed business operations and risk factors.
2. Track subsequent SEC filings for updates on the IPO timeline and details.
3. Analyze the company's financial projections and management team information once disclosed.

Key Dates

• 2024-01-19: Filing of S-1 Registration Statement — Initiation of public offering process

Year-Over-Year Comparison

This is the initial S-1 filing, so there is no prior filing to compare against for 'vs last filing' data.

Key Financial Figures

• $0.0001 — 0,000 shares of common stock, par value $0.0001 per share, of Azitra, Inc. The final pu
• $0 — ommon stock sold in this offering minus $0.001, the exercise price per share of co
• $2.05 — he closing sale of our common stock was $2.05. There is currently no established trad
• $8 million — ains. In December 2020, Bayer purchased $8 million of our Series B preferred stock, which
• $6.3 billion — s sold to AstraZeneca for approximately $6.3 billion in a staged acquisition in 2016. He als
• $21 billion — uently sold to Abbvie for approximately $21 billion in 2015. Before that, Mr. Salva spent a
• $17 billion — , the dermatology drug market surpassed $17 billion in 2021 and is expected to grow at a co
• $250 million — roduct candidate represents a potential $250 million global sales opportunity by mid-2030. O
• $1 billion — roduct candidate represents a potential $1 billion global sales opportunity by 2030. The d
• $39 m — notes, for the total gross proceeds of $39 million, all of which were converted into
• $5.00 — ommon stock at a price to the public of $5.00

Filing Documents

• forms-1.htm (S-1) — 2660KB
• ex4-4.htm (EX-4.4) — 125KB
• ex10-4.htm (EX-10.4) — 60KB
• ex23-2.htm (EX-23.2) — 4KB
• ex107.htm (EX-FILING FEES) — 34KB
• logo_001.jpg (GRAPHIC) — 12KB
• formdrs_002.jpg (GRAPHIC) — 393KB
• formdrs_003.jpg (GRAPHIC) — 83KB
• formdrs_004.jpg (GRAPHIC) — 82KB
• formdrs_005.jpg (GRAPHIC) — 105KB
• formdrs_006.jpg (GRAPHIC) — 75KB
• formdrs_007.jpg (GRAPHIC) — 61KB
• formdrs_008.jpg (GRAPHIC) — 30KB
• formdrs_009.jpg (GRAPHIC) — 41KB
• formdrs_010.jpg (GRAPHIC) — 12KB
• formdrs_011.jpg (GRAPHIC) — 32KB
• formdrs_012.jpg (GRAPHIC) — 19KB
• formdrs_013.jpg (GRAPHIC) — 24KB
• formdrs_014.jpg (GRAPHIC) — 42KB
• formdrs_015.jpg (GRAPHIC) — 16KB
• ex10-4_001.jpg (GRAPHIC) — 2KB
• ex10-4_002.jpg (GRAPHIC) — 2KB
• ex23-2_001.jpg (GRAPHIC) — 10KB
• 0001493152-24-002993.txt (&nbsp;) — 4320KB

RISK FACTORS

RISK FACTORS 9 SUMMARY FINANCIAL DATA 10 RISK FACTORS 11 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 36 TRADEMARKS, SERVICE MARKS AND TRADE NAMES 37 USE OF PROCEEDS 38 DIVIDEND POLICY 39 CAPITALIZATION 40

DILUTION

DILUTION 41 MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 42

BUSINESS

BUSINESS 51 MANAGEMENT 89 PRINCIPAL STOCKHOLDERS 96 DESCRIPTION OF SECURITIES 97 SHARES ELIGIBLE FOR FUTURE SALE 102 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS 103

UNDERWRITING

UNDERWRITING 107 LEGAL MATTERS 115 EXPERTS 115 WHERE YOU CAN FIND MORE INFORMATION 115 INDEX TO FINANCIAL STATEMENTS 116 You should rely only on the information contained in this prospectus. We have not authorized any other person to provide you with information different from or in addition to that contained in this prospectus, and we take no responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. No action is being taken in any jurisdiction outside the United States to permit a public offering of our common stock or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. As used in this prospectus, unless the context indicates or otherwise requires, &ldquo;the Company,&rdquo; &ldquo;our Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to Azitra, Inc., a Delaware corporation. INDUSTRY AND MARKET DATA This prospectus, particularly the section &ldquo;Business,&rdquo; contains observations, statistical data, estimates, and forecasts that are based on independent industry, government and non-government organization publications or other publicly available information, as well as other information based on our internal sources. Although we believe that the third-party sources referred to in this prospe

View Full Filing

View this S-1 filing on SEC EDGAR